Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
Aura Biosciences, Inc. (AURA) Create: Alert

All | News | Filings
Date FiledTypeDescription
10/02/2023 8-K Quarterly results
08/09/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/09/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports Second Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights Strengthened Clinical and Regulatory Leadership Team with Key Appointments Start-up Activities for the Global Phase 3 Trial Ongoing with Release of Drug Product Manufactured with Commercial Process and First Patient Expected to be Dosed in 2H 2023 BOSTON, MA – August 9, 2023 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the second quarter ended June 30, 2023, and provided clinical development and operational highlights. “As we build momentum across our portfolio, we are happy to welcome Drs. Bruce Brown and A...",
"OTHER SOLID TUMORS OCULAR ONCOLOGY"
06/07/2023 144 Form 144 - Report of proposed sale of securities:
06/07/2023 8-K Submission of Matters to a Vote of Security Holders  Interactive Data
06/02/2023 144 Form 144 - Report of proposed sale of securities:
05/11/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/11/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports First Quarter 2023 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration Guidance in Type C Meeting Supports Global Phase 3 Trial in Early-stage Choroidal Melanoma Enrollment Complete in Phase 2 Trial in Choroidal Melanoma Using Suprachoroidal Route of Administration BOSTON, MA – May 11, 2023 – Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the first quarter ended March 31, 2023, and provided clinical development and operational highlights. “We are encouraged by our recent interactions with the FDA in support of our global Phase 3 trial designed to en...",
"OTHER SOLID TUMORS OCULAR ONCOLOGY"
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/25/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/25/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
04/04/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION"
03/15/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
03/15/2023 10-K Annual Report for the period ended December 31, 2022
03/15/2023 8-K Quarterly results
Docs: "Aura Biosciences Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Clinical Development and Operational Highlights U.S. Food and Drug Administration Grants Fast Track Designation for Belzupacap Sarotalocan for the Treatment of Choroidal Metastasis, Bel-sar’s Second Ocular Oncology Indication to Receive this Designation Global Phase 3 Trial in Primary Choroidal Melanoma on Track to Begin Dosing in 1H 2023 BOSTON, MA – March 15, 2023 – Aura Biosciences, Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today reported financial results for the fourth quarter and year ended December 31, 2022, and provided clinical development and operational highlights. “2023 is off to a..."
02/14/2023 SC 13G EVENTIDE ASSET MANAGEMENT, LLC reports a 6.3% stake in Aura Biosciences, Inc.
02/14/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/10/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
02/09/2023 SC 13G/A ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.8% stake in Aura Biosciences, Inc.
01/20/2023 SC 13G/A Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
01/06/2023 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Corporate presentation of the Company",
"Corporate presentation of the Company"
12/15/2022 SC 13G ADAGE CAPITAL PARTNERS GP, L.L.C. reports a 5.6% stake in Aura Biosciences, Inc.
12/07/2022 SC 13D/A Matrix Capital Management Company, LP reports a 14.5% stake in Aura Biosciences, Inc.
12/05/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Underwriting Agreement, by and between the Company, SVB Securities, Cowen and Evercore ISI, as representatives of the several underwriters named therein",
"Opinion of Goodwin Procter LLP"
12/01/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/30/2022 424B5 Form 424B5 - Prospectus [Rule 424(b)(5)]:
11/30/2022 8-K Quarterly results
11/08/2022 EFFECT Form EFFECT - Notice of Effectiveness:
10/03/2022 8-K Quarterly results
09/28/2022 8-K Regulation FD Disclosure, Financial Statements and Exhibits  Interactive Data
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Aura Biosciences Announces First Patient Dosed in Phase 1study Evaluating Belzupacap Sarotalocan for the Treatment of Non-Muscle Invasive Bladder Cancer BOSTON, MA - September 28, 2022 - Aura Biosciences Inc. , a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate therapies for multiple oncology indications, today announced the first patient has been dosed in a Phase 1study evaluating belzupacap sarotalocan, the Company's first VDC product candidate, for the treatment of Non-Muscle Invasive Bladder Cancer . “Dosing of the first patient in this Phase 1study is an exciting key milestone both for Aura and for the field of urologic oncology, as approximately 70% of patients with bladder cancer globally are diagnosed early with NMIBC,” said Dr. Cadmus Rich..."
08/11/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/11/2022 8-K Quarterly results
06/30/2022 8-K Quarterly results
06/22/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy